PMC4937497_01
Prothrombin time/international normalized ratio (PT/INR) values and serum carcinoembryonic antigen (CEA) levels during regorafenib treatment. Only an important points are mentioned PT/INR values (day on course) after co-administration of regorafenib
40780_2016_50_Fig1_HTML.jpg
PMC4937497_01_40780_2016_50_Fig1_HTML.jpg
Fig1
The warfarin dose was increased up to 1.5 mg one month before initiation of treatment with regorafenib and up to 2 mg again when regorafenib was given concurrently (Fig. 1). Although the patient's PT/INR value was 1.26 before initiation of treatment with regorafenib, this value significantly increased to 2.1 on day 8, 2.98 on day 15, and 6.4 on day 22 (Fig. 1). His PT/INR value increased to 3.37 again on day 8 after restarting treatment with regorafenib (Fig. 1).